Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov 10;121(11):1279-1290.
doi: 10.1161/CIRCRESAHA.117.311827. Epub 2017 Sep 18.

Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)

Victoria Florea  1 , Angela C Rieger  1 , Darcy L DiFede  1 , Jill El-Khorazaty  1 , Makoto Natsumeda  1 , Monisha N Banerjee  1 , Bryon A Tompkins  1 , Aisha Khan  1 , Ivonne H Schulman  1 , Ana Marie Landin  1 , Muzammil Mushtaq  1 , Samuel Golpanian  1 , Maureen H Lowery  1 , John J Byrnes  1 , Robert C Hendel  1 , Mauricio G Cohen  1 , Krystalenia Valasaki  1 , Marietsy V Pujol  1 , Eduard Ghersin  1 , Roberto Miki  1 , Cindy Delgado  1 , Fouad Abuzeid  1 , Mayra Vidro-Casiano  1 , Russell G Saltzman  1 , Daniel DaFonseca  1 , Lina V Caceres  1 , Kevin N Ramdas  1 , Adam Mendizabal  1 , Alan W Heldman  1 , Raul D Mitrani  1 , Joshua M Hare  2
Affiliations
Clinical Trial

Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)

Victoria Florea et al. Circ Res. .

Abstract

Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure.

Objective: To compare the safety and efficacy of 2 doses of allogeneic bone marrow-derived human mesenchymal stem cells identically delivered in patients with ischemic cardiomyopathy.

Methods and results: Thirty patients with ischemic cardiomyopathy received in a blinded manner either 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocardial injection (0.5 cc per injection × 10 injections per patient). Patients were followed for 12 months for safety and efficacy end points. There were no treatment-emergent serious adverse events at 30 days or treatment-related serious adverse events at 12 months. The Major Adverse Cardiac Event rate was 20.0% (95% confidence interval [CI], 6.9% to 50.0%) in 20 million and 13.3% (95% CI, 3.5% to 43.6%) in 100 million (P=0.58). Worsening heart failure rehospitalization was 20.0% (95% CI, 6.9% to 50.0%) in 20 million and 7.1% (95% CI, 1.0% to 40.9%) in 100 million (P=0.27). Whereas scar size reduced to a similar degree in both groups: 20 million by -6.4 g (interquartile range, -13.5 to -3.4 g; P=0.001) and 100 million by -6.1 g (interquartile range, -8.1 to -4.6 g; P=0.0002), the ejection fraction improved only with 100 million by 3.7 U (interquartile range, 1.1 to 6.1; P=0.04). New York Heart Association class improved at 12 months in 35.7% (95% CI, 12.7% to 64.9%) in 20 million and 42.9% (95% CI, 17.7% to 71.1%) in 100 million. Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 million by 0.32 log pg/mL (95% CI, 0.02 to 0.62; P=0.039), but not in 100 million (-0.07 log pg/mL; 95% CI, -0.36 to 0.23; P=0.65; between group P=0.07).

Conclusions: Although both cell doses reduced scar size, only the 100 million dose increased ejection fraction. This study highlights the crucial role of cell dose in the responses to cell therapy. Determining optimal dose and delivery is essential to advance the field, decipher mechanism(s) of action and enhance planning of pivotal Phase III trials.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02013674.

Keywords: bone marrow; cell-based therapy; heart failure; hospitalization; stem cells.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study Flow Chart.
Following screening, 30 patients were enrolled and randomized 1:1 to receive allogeneic hMSC treatment. Following safety evaluation at 30 day TE-SAEs and secondary endpoints.
Figure 2.
Figure 2.. Changes in LV Function from Baseline to 12 months post-TESI.
(A) Ejection fraction increased from baseline in 100 M but not in 20 M: 3.7 units (IQR, 1.09, 6.10, p=0.04), between groups (p=0.68). (B) End diastolic volume, (C) end systolic volume, and (D) stroke volume did not improve from baseline. *within-group p≤0.05.
Figure 2.
Figure 2.. Changes in LV Function from Baseline to 12 months post-TESI.
(A) Ejection fraction increased from baseline in 100 M but not in 20 M: 3.7 units (IQR, 1.09, 6.10, p=0.04), between groups (p=0.68). (B) End diastolic volume, (C) end systolic volume, and (D) stroke volume did not improve from baseline. *within-group p≤0.05.
Figure 2.
Figure 2.. Changes in LV Function from Baseline to 12 months post-TESI.
(A) Ejection fraction increased from baseline in 100 M but not in 20 M: 3.7 units (IQR, 1.09, 6.10, p=0.04), between groups (p=0.68). (B) End diastolic volume, (C) end systolic volume, and (D) stroke volume did not improve from baseline. *within-group p≤0.05.
Figure 2.
Figure 2.. Changes in LV Function from Baseline to 12 months post-TESI.
(A) Ejection fraction increased from baseline in 100 M but not in 20 M: 3.7 units (IQR, 1.09, 6.10, p=0.04), between groups (p=0.68). (B) End diastolic volume, (C) end systolic volume, and (D) stroke volume did not improve from baseline. *within-group p≤0.05.
Figure 3.
Figure 3.. Changes in Scar Size from Baseline to 12 months post-TESI.
Both group reduced scar size and scar size as a fraction of LV mass by similar degree. (A) Scar size reduction in 20M by −6.4g (IQR, 13.5g, −3.4g, p=0.001) and 100M by −6.1g (IQR, −8.1g, −4.6g, p=0.0002), between groups (p=0.91). (B) Scar size as a percentage of LV mass decreased in 20M by 3.30% (−5.82%, −2.48%, p=0.0005) and 100M by 4.34% (−9.32%, −1.84%, p=0.0015), between groups (p=0.6). **Within-group p≤0.005, ***within-group p≤0.0005.
Figure 3.
Figure 3.. Changes in Scar Size from Baseline to 12 months post-TESI.
Both group reduced scar size and scar size as a fraction of LV mass by similar degree. (A) Scar size reduction in 20M by −6.4g (IQR, 13.5g, −3.4g, p=0.001) and 100M by −6.1g (IQR, −8.1g, −4.6g, p=0.0002), between groups (p=0.91). (B) Scar size as a percentage of LV mass decreased in 20M by 3.30% (−5.82%, −2.48%, p=0.0005) and 100M by 4.34% (−9.32%, −1.84%, p=0.0015), between groups (p=0.6). **Within-group p≤0.005, ***within-group p≤0.0005.
Figure 4.
Figure 4.. Functional Capacity and Quality of Life in ICM Patients.
Depicted are changes in functional capacity, quality of life, and sexual quality of life. (A) 6MWT distance increased in 20M by 13.5m (95% CI, −34.48m, 61.46m, p=0.57) and in 100M by 25.2m (95% CI, −23.20m, 73.58m, p=0.30), between groups (p=0.64). (B) NYHA class improved to a similar degree in both dose groups: 35.7% in 20M and 42.9% in 100M after 1 year post-TESI. (C) MLHFQ score didn’t change over time (20M p=0.22, 100M p=0.23). (D) pro-BNP was maintained in 100M while it increased by 0.32 log pg/mL (p=0.038) in 20M. *Within-group p≤0.05.
Figure 4.
Figure 4.. Functional Capacity and Quality of Life in ICM Patients.
Depicted are changes in functional capacity, quality of life, and sexual quality of life. (A) 6MWT distance increased in 20M by 13.5m (95% CI, −34.48m, 61.46m, p=0.57) and in 100M by 25.2m (95% CI, −23.20m, 73.58m, p=0.30), between groups (p=0.64). (B) NYHA class improved to a similar degree in both dose groups: 35.7% in 20M and 42.9% in 100M after 1 year post-TESI. (C) MLHFQ score didn’t change over time (20M p=0.22, 100M p=0.23). (D) pro-BNP was maintained in 100M while it increased by 0.32 log pg/mL (p=0.038) in 20M. *Within-group p≤0.05.
Figure 4.
Figure 4.. Functional Capacity and Quality of Life in ICM Patients.
Depicted are changes in functional capacity, quality of life, and sexual quality of life. (A) 6MWT distance increased in 20M by 13.5m (95% CI, −34.48m, 61.46m, p=0.57) and in 100M by 25.2m (95% CI, −23.20m, 73.58m, p=0.30), between groups (p=0.64). (B) NYHA class improved to a similar degree in both dose groups: 35.7% in 20M and 42.9% in 100M after 1 year post-TESI. (C) MLHFQ score didn’t change over time (20M p=0.22, 100M p=0.23). (D) pro-BNP was maintained in 100M while it increased by 0.32 log pg/mL (p=0.038) in 20M. *Within-group p≤0.05.
Figure 4.
Figure 4.. Functional Capacity and Quality of Life in ICM Patients.
Depicted are changes in functional capacity, quality of life, and sexual quality of life. (A) 6MWT distance increased in 20M by 13.5m (95% CI, −34.48m, 61.46m, p=0.57) and in 100M by 25.2m (95% CI, −23.20m, 73.58m, p=0.30), between groups (p=0.64). (B) NYHA class improved to a similar degree in both dose groups: 35.7% in 20M and 42.9% in 100M after 1 year post-TESI. (C) MLHFQ score didn’t change over time (20M p=0.22, 100M p=0.23). (D) pro-BNP was maintained in 100M while it increased by 0.32 log pg/mL (p=0.038) in 20M. *Within-group p≤0.05.
Figure 5.
Figure 5.. Effects of hMSCs on serum TNF-α in ICM Patients.
Cell treatment improved serum TNF-α at 6 months post-TESI by −5.96pg/mL in 20M (p=0.01) and −9.37pg/mL in 100M (p=0.0004), between groups (p=0.96). *Within-group p≤0.05, ***within-group p≤0.0005.
See this image and copyright information in PMC

Comment in

  • Posology for Regenerative Therapy.
    Terzic A, Behfar A. Terzic A, et al. Circ Res. 2017 Nov 10;121(11):1213-1215. doi: 10.1161/CIRCRESAHA.117.312074. Circ Res. 2017. PMID: 29122941 Free PMC article. No abstract available.

References

    1. de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Miano J, Koziner B, Bilos C, Altman PA. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the tabmmi study). American heart journal. 2007;154:79 e71–77 - PubMed
    1. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD, Cardiovascular Cell Therapy Research N. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The focus-cctrn trial. JAMA : the journal of the American Medical Association. 2012;307:1717–1726 - PMC - PubMed
    1. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circulation research. 2011;108:792–796 - PMC - PubMed
    1. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA, Investigators AC. Intramyocardial, autologous cd34+ cell therapy for refractory angina. Circulation research. 2011;109:428–436 - PMC - PubMed
    1. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA : the journal of the American Medical Association. 2012;308:2369–2379 - PMC - PubMed

Publication types

MeSH terms

Associated data